GE's Vizamyl gets European OK

GE Healthcare has received clearance from the European Commission to market Vizamyl (flutemetamol F-18 injection).

The radiopharmaceutical is indicated for PET imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment.

Vizamyl will be commercially available in select European countries beginning in early 2015.

Page 1 of 1243
Next Page